Application of in- vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action

Authors:
Su Liu , Lisa Razon , Olivia Ritchie , Choong-Ryoul Sihn , Britta Handyside , Geoffrey Berguig , Jill Woloszynek , Lening Zhang , Paul Batty , David Lillicrap , Vishal Agrawal , Christa Cortesio , Kahsay Gebretsadik , Hassibullah Akeefe , Peter Colosi , Benjamin Kim , Stuart Bunting , Sylvia Fong 
In:
Source: Mol Ther Methods Clin Dev.
Publication Date: (2022)
Issue: 26: 61-71
Research Area:
Gene Expression
Regenerative medicine
Cells used in publication:
Hepatocyte, human
Species: human
Tissue Origin: liver
Experiment

Primary hepatocytes were purchased from Lonza (Basel, Switzerland). Hepatocyte culture was performed in Bio-Coat collagen I 24-well plates (Corning, Corning, NY, USA), and thawing medium, plating medium, and maintenance medium (Lonza, Basel, Switzerland) were used for hepatocyte cell culture. Cryopreserved hepatocytes were thawed in a water bath set to 37C for less than 2 min. Once hepatocytes were almost completely thawed, the hepatocyte vial was wiped with 70% alcohol in the biosafety cabinet, and the cells were placed into the thawing medium using a wide-bore pipette tip to transfer. The thawing medium with the hepatocytes was inverted by hand prior to centrifugation. Human hepatocytes were centrifuged at 100  g for 10 min, NHP cells at 100  g for 6 min, and mouse hepatocytes at 70  g
for 5 min. Following centrifugation, the supernatant was aspirated, and cells were resuspended in 1 mL plating medium with a widebore
pipette to achieve single-cell suspension. The suspension was mixed with 5-mL plating medium, and hepatocytes were
diluted for ideal concentration for seeding (target concentration was approximately 1 million ± 20% cells/mL for humans and NHPs, 1 million ± 10% cells/well in a 24-well plate for dogs, and 0.45 million ± 10% cells/well in a 24-well plate for mice). Cells were evenly dispersed in the wells and then incubated.

In vitro AAV transduction Twenty hours after seeding, plates were removed from the incubator, and medium was aspirated and re-plated with 600 mL fresh hepatocyte
basal medium (HBM). The concentration of AAV virus was calculated based on MOI, and the AAV virus was prepared in the HBM at 2 times the target concentration. Following this, 450 mL HBM was removed, and 150 mL AAV containing HBM was added to each well (volume was adjusted for mouse cells to achieve comparable
MOIs). After 24 h, medium was removed, and cells were washed with HBM twice before 500 mL HBM with supplements (Lonza, Basel, Switzerland) were added per well. Cell cultures were maintained by changing medium each day, and 6 days following transduction, cells were collected for measurements.

Abstract

Recombinant adeno-associated virus (AAV) is an effective platform for therapeutic gene transfer; however, tissue-tropism differences between species are a challenge for successful translation of preclinical results to humans. We evaluated the use of in vitro primary hepatocyte cultures to predict in vivo liver-directed AAV expression in different species. We assessed whether in vitro AAV transduction assays in cultured primary hepatocytes from mice, nonhuman primates (NHPs), and humans could model in vivo liver-directed AAV expression of valoctocogene roxaparvovec (AAV5-hFVIII-SQ), an experimental gene therapy for hemophilia A with a hepatocyte-selective promoter. Relative levels of DNA and RNA in hepatocytes grown in vitro correlated with in vivo liver transduction across species. Expression in NHP hepatocytes more closely reflected expression in human hepatocytes than in mouse hepatocytes. We used this hepatocyte culture model to assess transduction efficacy of a novel liver-directed AAV capsid across species and identified which of 3 different canine factor VIII vectors produced the most transgene expression. Results were confirmed in vivo. Further, we determined mechanisms mediating inhibition of AAV5-hFVIII-SQ expression by concomitant isotretinoin using primary human hepatocytes. These studies support using in vitro primary hepatocyte models to predict species translatability of liver-directed AAV gene therapy and improve mechanistic understanding of drug-drug interactions.